About Savran Technologies

Savran Technologies develops non-invasive diagnostic tools that capture and analyze rare cells to detect diseases at early stages. This technology provides healthcare professionals with critical insights, enabling timely interventions that improve patient outcomes.

```xml <problem> Current diagnostic methods for diseases like cancer and complications in prenatal care often involve invasive procedures or lack the sensitivity to detect abnormalities at early stages. This can lead to delayed diagnoses and interventions, potentially impacting treatment outcomes and patient well-being. </problem> <solution> Savran Technologies is developing a platform for non-invasive diagnostics through the capture and analysis of ultra-rare cells from blood samples. Their patented microfluidic technology enables high-efficiency isolation of circulating tumor cells (CTCs) for cancer diagnostics and circulating fetal cells for prenatal diagnostics. The platform offers a streamlined workflow, eliminating the need for a centrifuge in some applications, and provides high purity and single-cell capture capabilities. By providing access to intact genomes and enabling early detection, Savran Technologies aims to improve patient outcomes through timely and targeted interventions. The technology has been validated in clinical trials for triple-negative breast cancer and is being developed for various tumor types and prenatal applications, including preeclampsia screening. </solution> <features> - Patented microfluidic design for efficient capture of ultra-rare cells from blood - High capture efficiency (90%+) and near-100% purity - Streamlined workflow, operable with or without a centrifuge - Gentle processing to maintain cell health for downstream analysis (fixed or live cells) - Scalable for high-throughput applications - Currently utilized in cancer diagnostics (CTC isolation for breast, lung, and pancreas cancers) - Developing assays for prenatal diagnostics (fetal cell isolation and genetic analysis) </features> <target_audience> The primary target audience includes researchers and clinicians in oncology and prenatal care, as well as diagnostic companies seeking to improve early disease detection and monitoring through non-invasive methods. </target_audience> ```

What does Savran Technologies do?

Where is Savran Technologies located?

Savran Technologies is based in Cambridge, United Kingdom.

When was Savran Technologies founded?

Savran Technologies was founded in 2018.

How much funding has Savran Technologies raised?

Savran Technologies has raised 7300000.

Location

Cambridge, United Kingdom

Founded

2018

Funding

7300000

Employees

7 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Savran Technologies

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

savrantech.com 300+

Crunchbase

Founded 2018 – Cambridge, United Kingdom

Funding

Estimated Funding

$5M+

Team (5+)

No team information available.

Company Description

Problem

Current diagnostic methods for diseases like cancer and complications in prenatal care often involve invasive procedures or lack the sensitivity to detect abnormalities at early stages. This can lead to delayed diagnoses and interventions, potentially impacting treatment outcomes and patient well-being.

Solution

Savran Technologies is developing a platform for non-invasive diagnostics through the capture and analysis of ultra-rare cells from blood samples. Their patented microfluidic technology enables high-efficiency isolation of circulating tumor cells (CTCs) for cancer diagnostics and circulating fetal cells for prenatal diagnostics. The platform offers a streamlined workflow, eliminating the need for a centrifuge in some applications, and provides high purity and single-cell capture capabilities. By providing access to intact genomes and enabling early detection, Savran Technologies aims to improve patient outcomes through timely and targeted interventions. The technology has been validated in clinical trials for triple-negative breast cancer and is being developed for various tumor types and prenatal applications, including preeclampsia screening.

Features

Patented microfluidic design for efficient capture of ultra-rare cells from blood

High capture efficiency (90%+) and near-100% purity

Streamlined workflow, operable with or without a centrifuge

Gentle processing to maintain cell health for downstream analysis (fixed or live cells)

Scalable for high-throughput applications

Currently utilized in cancer diagnostics (CTC isolation for breast, lung, and pancreas cancers)

Developing assays for prenatal diagnostics (fetal cell isolation and genetic analysis)

Target Audience

The primary target audience includes researchers and clinicians in oncology and prenatal care, as well as diagnostic companies seeking to improve early disease detection and monitoring through non-invasive methods.